Barclays PLC Raises Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Barclays PLC boosted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAFree Report) by 7.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 175,525 shares of the company’s stock after acquiring an additional 12,867 shares during the quarter. Barclays PLC’s holdings in Kiniksa Pharmaceuticals were worth $3,048,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its position in Kiniksa Pharmaceuticals by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 128,778 shares of the company’s stock valued at $1,813,000 after acquiring an additional 828 shares during the period. Legal & General Group Plc increased its position in shares of Kiniksa Pharmaceuticals by 7.8% during the 4th quarter. Legal & General Group Plc now owns 11,712 shares of the company’s stock valued at $175,000 after purchasing an additional 850 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Kiniksa Pharmaceuticals by 0.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 205,557 shares of the company’s stock valued at $3,079,000 after purchasing an additional 1,057 shares during the period. Royal Bank of Canada increased its position in shares of Kiniksa Pharmaceuticals by 44.2% during the 2nd quarter. Royal Bank of Canada now owns 3,523 shares of the company’s stock valued at $50,000 after purchasing an additional 1,080 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Kiniksa Pharmaceuticals by 19.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,549 shares of the company’s stock valued at $83,000 after purchasing an additional 1,385 shares during the period. 47.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. TheStreet cut Kiniksa Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, November 3rd. Wedbush lifted their price target on Kiniksa Pharmaceuticals from $23.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, January 2nd.

View Our Latest Analysis on KNSA

Kiniksa Pharmaceuticals Stock Up 1.3 %

KNSA opened at $20.55 on Tuesday. The firm has a market cap of $1.45 billion, a PE ratio of -186.80 and a beta of 0.24. The business has a fifty day simple moving average of $18.39 and a 200-day simple moving average of $17.27. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $10.29 and a fifty-two week high of $20.94.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, insider John F. Paolini sold 28,600 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $17.65, for a total transaction of $504,790.00. Following the completion of the sale, the insider now directly owns 44,892 shares of the company’s stock, valued at approximately $792,343.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CAO Michael R. Megna sold 9,316 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $19.13, for a total transaction of $178,215.08. Following the completion of the sale, the chief accounting officer now directly owns 17,005 shares of the company’s stock, valued at approximately $325,305.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 28,600 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $17.65, for a total value of $504,790.00. Following the sale, the insider now directly owns 44,892 shares of the company’s stock, valued at $792,343.80. The disclosure for this sale can be found here. Insiders sold a total of 66,586 shares of company stock valued at $1,242,569 in the last three months. 54.23% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals Profile

(Free Report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Read More

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAFree Report).

Institutional Ownership by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.